pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Jaypirca
drug · small molecule
save

pirtobrutinib

Marketedupdated 6mo ago
by Eli Lilly and Co🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval16 co-mentions · 4 sources
  • tagSmall Molecule8 co-mentions · 4 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 3 investigational indications.

targets

Tyrosine-protein kinase BTK

all catalysts(0)

nothing on the calendar yet

Trials studying pirtobrutinib

  • phase2A Study of Pirtobrutinib in Participants With Immune Thrombocytopeniarecruitingn=68
  • phase3A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomarecruitingn=500
  • phase3Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)active not recruitingn=500
  • phase2Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLrecruitingn=60
  • phase2Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndromeactive not recruitingn=194
  • phase3A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).not yet recruitingn=280
  • phase3ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLrecruitingn=306
  • phase4A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomarecruitingn=150

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 27, 2028
~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

  • Sep 14, 2041formulationUS 12109193
  • Sep 14, 2041formulationUS 12109193
  • Jul 29, 2039formulationUS 12268666
  • Jul 29, 2039formulationUS 12268666
  • Dec 16, 2036compositionUS 10342780
  • Dec 16, 2036compositionUS 10342780
  • Dec 16, 2036method-of-use (U-4362)US 10464905
  • Dec 16, 2036method-of-use (U-4362)US 10464905
  • Dec 16, 2036compositionUS 10695323
  • Dec 16, 2036compositionUS 10695323
  • Dec 16, 2036method-of-use (U-4362)US 10918622
  • Dec 16, 2036method-of-use (U-4362)US 10918622
  • Dec 16, 2036compositionUS 12220401
  • Dec 16, 2036compositionUS 12220401

FDA exclusivities (8)

  • Dec 1, 2030ODE-451Orphan Drug (7y)4.0y
  • Dec 1, 2030ODE-451Orphan Drug (7y)4.0y
  • Jan 27, 2030ODE-424Orphan Drug (7y)3.2y
  • Jan 27, 2030ODE-424Orphan Drug (7y)3.2y
  • Dec 2, 2028I-981Indication (3y)2.0y
  • Dec 2, 2028I-981Indication (3y)2.0y
  • Jan 27, 2028NCENew Chemical Entity (5y)1.2y
  • Jan 27, 2028NCENew Chemical Entity (5y)1.2y

News(10)

  • Nurix drops one BTK degrader as momentum builds behind Roche-partnered option
    Nurix’s BTK degrader zelebrudomide may have survived a clinical hold in recent years, but that hasn’t stopped the California biotech from dropping the cancer drug.
    fiercebiotech · 1mo ago
  • STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few
    Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.
    stat · 1mo ago
  • STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
    Caribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.
    stat · 1mo ago
  • STAT+: AstraZeneca opens new Boston site
    AstraZeneca opened a new R&D site in Kendall Square yesterday, celebrating a $1 billion investment in the unsettled center of U.S. biotechnology after a spate of Chinese dealmaking.
    stat · 1mo ago
  • STAT+: Are stem cell treatments about to have their day?
    Stem cells might be the next peptides, and how Trump's $90 checks will play out after the election.
    stat · 1mo ago
  • Opinion: Why the FDA should not approve an ineffective multicancer screening test
    “Telling more people they have cancer is not progress; progress is having fewer people die from cancer,” H. Gilbert Welch writes of Grail’s multicancer screening test.
    stat · 1mo ago
  • STAT+: Judges skewer HHS arguments in hearing over Medicare Advantage audits lawsuit
    Federal judges pushed back against the government's arguments in a Medicare Advantage case.
    stat · 1mo ago
  • STAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s
    Optogenetics is now the foundational way through which we are able to understand how the brain works
    stat · 1mo ago
  • STAT+: New Trump regulations would clean up health care pricing disclosures
    The Trump administration is continuing its effort to bring more transparency to the cost of health care.
    stat · 1mo ago
  • STAT+: Prices, prices, prices
    Why is health insurance so expensive? Read the latest stort in STAT's "Out of Pocket, Out of Reach" series to find out.
    stat · 1mo ago
view all news mentions →
brand
Jaypirca
trade names
Jaypirca
generic
pirtobrutinib
MOA
Tyrosine-protein kinase BTK inhibitor
indication
Chronic Lymphocytic Leukemia (CLL)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?